8-KCorporate ChangesExhibits & Filings

PFIZER INC 8-K Report, Bylaw Amendment (Oct 24, 2008)

Filed October 24, 2008For Securities:PFE

Summary

Pfizer Inc. (PFE) filed an 8-K report on October 24, 2008, detailing amendments to its By-laws approved by the Board of Directors on October 23, 2008. The most significant change relates to the calling of special meetings of stockholders. Previously, the conditions for calling a special meeting were not explicitly stated in this filing. The amendment now requires a written request from record holders of at least 25% of the total voting shares to compel the Chair of the Board or the Secretary to call such a meeting. These amendments also include conforming changes to other sections of the By-laws, specifically those pertaining to the number of directors, their election and term, and the procedures for director nominations by stockholders. This update to the By-laws may impact shareholder engagement and governance dynamics by potentially making it easier for a significant block of shareholders to convene special meetings for important matters.

Key Highlights

  • 1Pfizer's Board of Directors approved amendments to the company's By-laws on October 23, 2008.
  • 2The By-laws were amended to change Article I, Section 9 (Special Meetings).
  • 3Special stockholder meetings can now be called at the written request of stockholders holding at least 25% of the total voting shares.
  • 4This 25% threshold requires a written request to either the Chair of the Board or the Secretary.
  • 5Conforming and related changes were made to By-law sections concerning director election, term, and nomination procedures.
  • 6The amended By-laws are filed as Exhibit 3.1 to this 8-K report.

Frequently Asked Questions

The primary change is to the section governing special meetings of stockholders. The By-laws now specify that the Chair of the Board or the Secretary shall call a special meeting if requested in writing by shareholders who collectively hold at least 25% of the total voting shares.

This threshold provides a mechanism for significant shareholders to convene a special meeting to discuss and vote on matters of importance to them. It potentially empowers a larger group of shareholders to have their concerns addressed by management and the Board more directly and promptly than waiting for an annual meeting.

Yes, the filing also mentions related and conforming changes made to other sections of the By-laws. These include amendments to provisions concerning the number of directors, their election and terms, and the eligibility and procedures for stockholder nominations of directors.

The full text of Pfizer's amended and restated By-laws, as of October 23, 2008, is attached as Exhibit 3.1 to this Form 8-K filing.